RT Journal Article
SR Electronic
T1 Triglyceride Glucose Index Predicts Risk of Adverse Cardio-metabolic and Mortality Outcomes Among Chinese Adults: A Territory-Wide Longitudinal Study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.01.04.21249208
DO 10.1101/2021.01.04.21249208
A1 Jiandong Zhou
A1 Sharen Lee
A1 Jeremy Hui
A1 Wing Tak Wong
A1 Keith SK Leung
A1 Abraham KC Wai
A1 Tong Liu
A1 Bernard Man Yung Cheung
A1 Gary Tse
A1 Qingpeng Zhang
YR 2021
UL http://medrxiv.org/content/early/2021/01/05/2021.01.04.21249208.abstract
AB Background The triglyceride glucose (TyG) index has been proposed to be a surrogate of insulin resistance. In the study, we aimed to examine the relationship between TyG index and the risk of new onset DM and secondary outcomes included atrial fibrillation (AF), heart failure (HF), acute myocardial infarction (AMI), ventricular tachycardia/fibrillation (VTF), cardiovascular mortality (CAD) and all-cause mortality.Methods The retrospective observational study analyzed patients recruited from 1st January 2000 to 31st December 2003 and followed up until 31st December 2019. Demographics, past comorbidities, medications and laboratory tests were extracted. At baseline and follow-up, DM was defined as 1) any occasion Hb1Ac ≥14 g/dL, 2) fasting glucose≥7 mmol/L on two occasions, or 3) with DM diagnosis. We excluded 1) patients with prior DM or with the use of antidiabetic medications; 2) patients with prior AMI/HF/AF or with the use of diuretic/beta blockers for HF were excluded. Univariate analysis and multivariate Cox analysis with adjustments on demographics, past comorbidities and medications were conducted to identify the significant risk predictors of primary and secondary outcomes. Optimal cutoffs of TyG index for the primary and secondary outcomes were found with maximally selected rank statistics approach.Result Lager TyG index is significantly associated with new onset DM (HR: 1.51, 95% CI: [1.47, 1.55], P vlaue<0.0001), new onset HF (HR: 1.27, 95% CI: [1.2, 1.34], P vlaue<0.0001), new onset AF (HR: 2.36, 95% CI: [2.26, 2.46], P vlaue<0.0001), new onset AMI (HR: 1.51, 95% CI: [1.42, 1.6], P vlaue<0.0001), new onset VTF (HR: 1.22, 95% CI: [1.13, 1.31], P vlaue<0.0001), new onset CAD (HR: 1.56, 95% CI: [1.45, 1.69], P value<0.0001) and all-cause mortality (HR: 1.21, 95% CI: [1.18, 1.25], P vlaue<0.0001). TyG index and its 3rd tertile remained significant after being adjusted with significant demographics, past comorbidities and medicactions in multivariate cox models (HR>1, P value<0.05). Optimal cut-off values of baseline TyG index and adjusted multivariate restricted cubic spline models further uncovered detailed associations of larger baseline TyG index with the primary and secondary outcome.Conclusion Higher TyG index remained significantly associated with the elevated risk of new onset DM, AF, HF, AMI, VTF, CAD and all-cause mortality after adjustments on demographics, past comorbidities, and medications.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNoneAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by The Joint Chinese University of Hong Kong - New Territories East Cluster Clinical Research Ethics Committee and Institutional Review Board of the University of Hong Kong/Hospital Authority Hong Kong West Cluster.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData available upon request.